Search
COVID19 Paid Clinical Trials in Georgia
A listing of 13 COVID19 clinical trials in Georgia actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 13
The state of Georgia currently has 13 active clinical trials seeking participants for COVID19 research studies. These trials are conducted in various cities, including Atlanta, Augusta, Decatur and Savannah.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
COVID-19 Vaccination for Children
Recruiting
The purpose of this clinical trial is to evaluate a booster dose of mRNA-1273.815, Moderna’s investigational COVID-19 vaccine, to learn more about whether the investigational vaccine is safe when given as a booster that is the same dose as an initial COVID-19 vaccination.
Featured Trial
Cardiovascular Disease Trials
Recruiting
Cardiovascular Disease trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Cardiovascular Disease
Featured Trial
Overweight Trials
Recruiting
Overweight trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Overweight
Featured Trial
Low back pain Trials
Recruiting
Low back pain trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Low back pain
Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Recruiting
Primary objective:
- To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19.
Secondary objectives:
- To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality.
Safety objectives:
- To evaluate the safety of oral reparixin versus placebo in the specific cli... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Emory Johns Creek Hospital, Atlanta, Georgia +1 locations
Conditions: Infectious Pneumonia, Severe COVID-19
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
Recruiting
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19).
The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for... Read More
Gender:
All
Ages:
Between 0 years and 17 years
Trial Updated:
06/03/2024
Locations: Children's Healthcare of Atlanta - Egleston Hospital, Atlanta, Georgia +2 locations
Conditions: COVID-19
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
Recruiting
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Emory Grady (Site 301-032), Atlanta, Georgia +1 locations
Conditions: COVID-19
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
Recruiting
The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children. The trial is divided into 5 individual studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies will receive study vaccine as a shot depending on what group they are in.
Substudy A design: Phase 1 includes participant... Read More
Gender:
All
Ages:
Between 6 months and 11 years
Trial Updated:
05/13/2024
Locations: Emory University School of Medicine, Atlanta, Georgia +5 locations
Conditions: SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Emory University, Atlanta, Georgia
Conditions: COVID-19
Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19
Recruiting
This is a randomized, double-blind, sham controlled, stratified, pivotal efficacy and safety study of the EmitBio RD-X19 treatment device in Individuals 40 Years of age and older with Mild COVID-19 in the at-home setting.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/11/2024
Locations: 341 - Lifeline Primary Care / CCT Research, Lilburn, Georgia
Conditions: COVID-19
Arginine Replacement Therapy in COVID-19
Recruiting
The purpose of this study is to investigate if receiving doses of arginine (a protein in the body) will improve mitochondria function in children with COVID-19.
The study will be performed in Children's Healthcare of Atlanta, Egleston campus. Patients will be randomized to receive one of three doses of arginine three times a day for five days or at discharge whichever comes first.
Gender:
All
Ages:
Between 3 years and 21 years
Trial Updated:
02/26/2024
Locations: Children's Healthcare of Atlanta (CHOA), Egleston, Atlanta, Georgia
Conditions: COVID-19
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Recruiting
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.
The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.
In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.
REMAP-COVID is a sub-platform of REMAP-CAP th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/25/2024
Locations: Augusta University, Augusta, Georgia
Conditions: Community-acquired Pneumonia, Influenza, COVID-19
Promoting Engagement and COVID-19 Testing for Health
Recruiting
PEACH2 is a community-based study, targeting individuals affected by diabetes. Study participants will be randomized into the PEACH2 Intervention Arm or the Control Arm. The intervention lasts for 16 weeks and participants will be followed for 12 months in total.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: Emory University, Atlanta, Georgia
Conditions: COVID-19
COVID-19 Outcome Prediction Algorithm
Recruiting
Severe acute respiratory syndrome coronavirus 2-mediated coronavirus disease (COVID-19) is an evolutionarily unprecedented natural experiment that causes major changes to the host immune system. We propose to develop a test that accurately predicts short- and long-term (within one-year) outcomes in hospitalized COVID-19 patients broadly reflecting US demographics who are at increased risk of adverse outcomes from COVID-19 using both clinical and molecular data. We will enroll patients from a hos... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2023
Locations: Atlanta VA Medical Center, Decatur, Georgia
Conditions: COVID-19, Post Acute Sequelae of COVID-19, Long COVID, Organ Dysfunction Syndrome, Multiple, Frailty Syndrome
Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults
Recruiting
A randomized, observer-blind, placebo-controlled immuno-bridging, and broadening study to demonstrate the equivalence of the immune response between participants enrolled in Phase 3 efficacy trial in India and demographically diverse healthy adult participants in the US which matched in age and vaccine formulation setting to whom those efficacy results are extrapolated; and to assess the broadening of the BBV152 in participants who previously received two shots of messenger ribonucleic acid (mRN... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/24/2023
Locations: IACT Health, Columbus, Georgia
Conditions: COVID-19
A Phase 1/2 Study to Assess the Safety and Immunogenicity of JCXH-221, an mRNA-based Broadly Protective COVID-19 Vaccine
Recruiting
The goal of this clinical trial is to learn about, test, and compare JCXH-221 in healthy volunteers. The main aims to answer are:
To assess the safety and tolerability of the JCXH-221 vaccine in healthy adult subjects
To identify an optimal dose for the JCXH-221 vaccine in healthy adult subjects
To assess the humoral immunogenicity of the JCXH-221 vaccine in healthy adult subjects
To characterize the cellular immunogenicity of the JCXH-221 vaccine in healthy adult subjects
Participants for Pha... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/16/2023
Locations: Velocity Clinical Research, Savannah, Georgia
Conditions: COVID-19, Infectious Disease
1 - 12 of 13